cropper
update
Pulse On Wellcare
update
  • Home
  • Categories
    • Healthcare
    • Trends
    • Insights
    • Southwest
    • Strategies
    • Prevention
    • Lifestyle
    • Mental Health
    • Preventative Care
    • Nutrition & Meal Planning
    • Telemedicine Access
    • Workplace Wellness
    • Wellness Tips
  • Events
  • Healthy Aging
December 19.2025
2 Minutes Read

Discover How Orforglipron Helps Maintain Weight Loss for Obesity Management

Orforglipron Weight Loss Maintenance: syringe with measuring tape.

Orforglipron: A Breakthrough in Weight Loss Maintenance

The recent announcement from Eli Lilly regarding the results of the ATTAIN-MAINTAIN trial showcases orforglipron, an innovative oral GLP-1 receptor agonist. This groundbreaking medication appears to help individuals maintain weight loss after transitioning from injection therapies like Wegovy and Zepbound. The phase 3 trial indicates that orforglipron not only assists in retaining weight lost during previous treatments but also offers a more convenient, needle-free alternative that could revolutionize weight management for many.

Understanding the Study Results: Key Findings from ATTAIN-MAINTAIN

In the ATTAIN-MAINTAIN trial, 376 participants who previously achieved significant weight loss in the SURMOUNT-5 study were assessed for their ability to maintain this weight loss using orforglipron compared to a placebo. Remarkably, orforglipron demonstrated superior performance, with patients maintaining an average weight difference of 0.9 kg when switching from Wegovy and 5.0 kg from Zepbound after 52 weeks. This suggests a promising option for patients who have plateaued in their weight loss journey following injectable treatment.

The Importance of Weight Maintenance in Long-term Health

Obesity is often described as a chronic condition that requires long-term management strategies. Experts note that sustaining weight loss is particularly challenging, with many individuals regaining weight after ceasing their injection treatments. With orforglipron, patients may find a sustainable alternative that encourages weight maintenance without the physical encumbrance of weekly injections. As stated by Kenneth Custer, president of Lilly Cardiometabolic Health, ensuring long-term health in individuals living with obesity is paramount.

Potential Impacts on the Market and Treatment Choices

The implications of orforglipron’s trial results could reshape the pharmaceutical landscape for obesity treatments. While existing injections like Wegovy and Zepbound have proven effective, the ease of an oral medication might attract more patients. Analysts predict that Eli Lilly’s pill could capture a significant market share, estimated at $2 billion in sales by the end of 2026. Patients previously deterred by injections may now have a viable, appealing option to help maintain their weight loss.

Challenges Ahead: Pricing and Accessibility

Despite the promising results, a critical question looms: Will orforglipron be accessible and affordable for the average patient? The cost of injectable obesity treatments currently stands at about $1,000 per month, presenting a financial barrier for many. Eli Lilly plans to introduce their oral drug at a lower price point in partnership with the TrumpRx initiative. However, effective insurance coverage and affordability will be pivotal in determining how many patients can benefit from this new treatment.

Final Thoughts: The Future of Obesity Treatment

Orforglipron's development not only highlights a significant advancement in obesity treatment but emphasizes the importance of providing multiple therapeutic options for individuals struggling with weight management. As Eli Lilly awaits FDA approval, the dialogue around sustainable obesity treatment continues to expand. This trial signals hope—offering potential avenues for patients to achieve and maintain lasting health improvements.

Strategies

14 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
05.22.2026

Nursing and PA Programs Excluded from Student Loan Benefits: A Disheartening Reality

Update Understanding the Exclusion of Nurses from Federal Loan Programs In a move that has left many in the nursing profession both confused and disheartened, the U.S. Department of Education's decision to exclude nursing and physician assistant (PA) programs from its professional degree list has sparked widespread criticism. The new federal student loan regulations, rolled out as part of the Trump Administration's One Big Beautiful Bill Act, establish dramatically lower borrowing caps for these crucial healthcare education pathways. By limiting the financial resources available to nursing and PA students, this policy raises serious questions about the future workforce of America’s healthcare system. The Implications of Financial Exclusion The hefty $200,000 lifetime cap for professional degrees like medicine and law is a stark contrast to the significantly lower borrowing limits set for graduate nursing students. With the exclusion of vital healthcare roles from this list, nursing students find themselves at an educational and financial disadvantage, potentially impacting their ability to pursue advanced degrees. According to the American Nurses Association, over 236,000 nurses and patients have already signed a petition urging the Department of Education to reverse this decision. The Ripple Effects on Healthcare Diversity Recent studies emphasize how these new loan caps could exacerbate existing disparities within the healthcare workforce. Dr. Hao Yu from Harvard Medical School has noted that higher interest rates associated with private loans might deter lower-income students from pursuing advanced nursing education. This financial barrier can have lasting implications on the diversity of the physician workforce, often resulting in a lack of representation for underprivileged communities. As healthcare professionals who frequently practice in underserved areas, nurse practitioners and certified registered nurse anesthetists are critical, especially in rural regions. Voices of Dissent in the Nursing Community National Nurses United (NNU) has vocally opposed this ruling, framing the loan exclusion as an attack not just on the profession but also on advancing education for women and working-class individuals. The NNU's statement highlights the gender disparities within nursing—a field predominantly composed of females—and stresses the need for supportive policies that facilitate educational advancement rather than restrict it. Long-Term Concerns for the Healthcare System The consequence of these regulations may go beyond the immediate educational crisis. As projected by the Health Resources and Services Administration, the U.S. is expected to face a significant physician shortage in the coming years, further exacerbated by these loan cap restrictions. The potential of driving away qualified nursing professionals from further education could deepen this healthcare gap. What Stakeholders Can Do As healthcare stakeholders, educators, and advocates unite to confront these challenges, active participation in the ongoing public comment period for the Department of Education's ruling is critical. By voicing discontent and sharing experiences, individuals can urge revisions that promote an inclusive education model that values nursing as a professional degree path. A Call to Action For those invested in the future of healthcare, it is imperative to join the advocacy efforts led by organizations like the American Nurses Association and National Nurses United. Engaging in public comments, contacting lawmakers, and sharing personal stories can influence policy changes that support the continued growth and diversity of the nursing workforce. The future of healthcare depends on educated, skilled professionals who reflect the communities they serve.

05.21.2026

Burnout Rates in Medicine: What Every Future Doctor Should Know

Update Understanding the Landscape of Physician BurnoutBurnout among physicians is a growing concern, affecting around 41.9% of medical professionals, according to the American Medical Association (AMA). Despite a gradual decline from more severe rates over recent years, this issue demands attention. The AMA’s 2025 National Physician Comparison Report reveals alarming disparities among specialties, particularly where burnout rates remain high. Emergency medicine, urological surgery, and hematology/oncology lead the pack, each hovering near or exceeding 49%.A Deeper Dive into SpecialtiesThe AMA's findings demonstrate that job stress and administrative burdens vary significantly across medical fields. Surprising insights reveal that while some specialties, like dermatology and infectious diseases, report lower burnout rates (23.3% and 31.6% respectively), others such as anesthesiology and general surgery echo the opposite. Job environments, along with specific expectations and responsibilities, contribute heavily to these outcomes.Contributing Factors to BurnoutA study highlighted that nearly one in four physicians, particularly in high-stress environments, are considering leaving their careers largely due to excessive bureaucratic work and the overwhelming demands of electronic health records (EHRs). Current research indicates that physicians are spending roughly two hours on administrative duties for every hour with a patient—an unsustainable ratio that exacerbates stress levels.Strategies for Burnout PreventionHealth organizations, such as Bayhealth, are making strides in addressing burnout through creative solutions like enhancing workplace culture, implementing technology to reduce clerical tasks, and fostering community among physicians. Efforts like a “buddy” system for new physicians and the utilization of ambient AI dictation tools are just a few innovations that have garnered recognition for their success in promoting well-being.What Medical Students Should ConsiderAs medical students begin to select specialties, understanding these trends in burnout can be crucial. Dermatology, internal medicine, and pediatrics show lower rates of burnout and higher job satisfaction. In contrast, fields like anesthesiology and general surgery present significant challenges that could lead to career dissatisfaction. The choice of specialty should weigh personal interests alongside the potential for burnout.The Role of Autonomy and FlexibilityResearch consistently highlights that job satisfaction correlates with the degree of autonomy and flexibility physicians experience in their roles. Specialties offering better scheduling control often report lower instances of burnout. Pursuing practices that offer flexibility, such as locum tenens positions, could transform how burnout is experienced across various specialties.Conclusion: The Need for a Collective Shift in HealthcareWith nearly half of U.S. physicians expressing that their teams are understaffed, immediate action is necessary to restructure how healthcare is delivered. Strategies that prioritize organizational change and administrative reduction promise not just relief from burnout but also a rejuvenated healthcare workforce ready to tackle the challenges of the modern medical environment. As medical students progress in their careers, they must advocate for systems that support their well-being along with patient health.

05.19.2026

The FDA Expands Use of T-DXd: A Milestone for Early HER2+ Breast Cancer Treatment

Update Why T-DXd is a Game Changer in Breast Cancer Care The recent FDA approval of trastuzumab deruxtecan (T-DXd) for early HER2-positive breast cancer marks a pivotal moment in oncology. This drug is expanding into both neoadjuvant and adjuvant treatment settings, providing hope for a curative approach where previously there was limited success. Breakthrough Approvals That Reshape Treatment Protocols The newly approved indications mean that more patients can receive T-DXd prior to surgery (neoadjuvant) and after surgery (adjuvant). In the neoadjuvant context, T-DXd is used in conjunction with standard therapies such as taxanes and other monoclonal antibodies, significantly enhancing the chances of achieving a pathologic complete response. In clinical trials, over two-thirds of the participants receiving T-DXd achieved this outcome, compared to just 56% with traditional treatments, highlighting a clear advantage. The Evidence Behind the Approval This approval is rooted in data from two noteworthy phase 3 clinical trials—DESTINY-Breast11 and DESTINY-Breast05. The DESTINY-Breast11 trial demonstrated that patients who received a T-DXd-based regimen had over a 50% improvement in disease-free survival compared to those who received the standard treatment of trastuzumab emtansine. Meanwhile, the DESTINY-Breast05 trial further affirms T-DXd’s efficacy, showing a remarkable 53% reduction in the risk for invasive disease recurrence. Companion Diagnostics: A Step Forward in Personalized Medicine With the expansion of T-DXd use, the FDA also cleared two companion diagnostic tests—the PATHWAY anti-HER2/neu antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail. These tests ensure that only eligible HER2-positive patients receive T-DXd, optimizing treatment through targeted therapy. What Comes Next: Monitoring Safety and Efficacy While T-DXd offers promising advantages, it’s important to discuss potential side effects. Commonly reported issues include nausea, fatigue, and low blood counts, signaling the need for careful monitoring during treatment. The prescribing information also includes critical precautions for interstitial lung disease and embryo-fetal toxicity, highlighting the potential risks involved. Looking Forward: The Future of HER2-Positive Breast Cancer Treatment As Dr. Shanu Modi from Memorial Sloan Kettering Cancer Center notes, these approvals will transform how we treat early HER2-positive breast cancer, potentially altering the landscape of outcomes for many patients. T-DXd’s growing list of indications now emphasizes the importance of ongoing research and the need for continuous refinement of treatment strategies. The FDA's approval of T-DXd reflects the rapid progress in breast cancer therapies. As we continue to see advancements, patients can remain hopeful as new treatments open doors to more effective and comprehensive care.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*